Seladelpar in patients with primary biliary cholangitis: Need for a closer look!

J Hepatol. 2022 Nov;77(5):1451. doi: 10.1016/j.jhep.2022.04.039. Epub 2022 May 17.

Authors

Ajay Kumar Mishra¹, Satender Pal Singh²

Affiliations

¹ Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
² Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India. Electronic address: ama.satender@gmail.com.

PMID: 35594993
DOI: 10.1016/j.jhep.2022.04.039

No abstract available

Keywords: Fibrosis; PBC; PPAR delta; Seladelpar; UDCA.

Publication types

Letter
Comment

MeSH terms

Acetates
Cholagogues and Choleretics / therapeutic use
Cholangitis* / drug therapy
Cholangitis* / etiology
Humans
Liver Cirrhosis, Biliary* / complications
Liver Cirrhosis, Biliary* / diagnosis
Liver Cirrhosis, Biliary* / drug therapy
Ursodeoxycholic Acid / therapeutic use

Substances

Acetates
Cholagogues and Choleretics
Ursodeoxycholic Acid
seladelpar